In situ transport of vinblastine and selected P-glycoprotein substrates: Implications for drug-drug interactions at the mouse blood-brain barrier

Pharmaceutical Research

Volumn 21, Issue 8, 2004, Pages 1382-1389

  Cisternino, Salvatore ^a   Rousselle, Christophe ^a   Debray, Marcel ^b   Scherrmann, Jean Michel ^a  

^a HÔPITAL FERNAND WIDAL   (France)

^b Faculte de Pharmacie   (France)

Author keywords

blood brain barrier; in situ brain perfusion; multidrug resistance; P glycoprotein; vinblastine

Indexed keywords

COLCHICEINE; GLYCOPROTEIN P; MORPHINE; PROGESTERONE; VALSPODAR; VERAPAMIL; VINBLASTINE;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CITRIC ACID CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TRANSPORT; EXPERIMENTAL MODEL; IC 50; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; COLCHICINE; CYCLOSPORINS; DEXAMETHASONE; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED STRAINS; MORPHINE; P-GLYCOPROTEIN; PROGESTERONE; QUINIDINE; VERAPAMIL; VINBLASTINE;

EID: 4344577850     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000036911.49191.da     Document Type: Article

References (41)

1. H. Sun, H. Dai, N. Shaik, and W. F. Elmquist. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55:83-105 (2003).
2. T. Eisenblatter and H. J. Galla. A new multidrug resistance protein at the blood-brain barrier. Biochem. Biophys. Res. Commun. 293:1273-1278 (2002).
3. S. V. Ambdukar, S. Dey, and C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398 (1999).
4. A. Seelig. and E. Landwojtowicz. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 12:31-40 (2000).
5. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. Mol. and P. Borst. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705 (1995).
6. S. Cisternino. F. Bourasset, Y. Archimbaud, D. Semiond, G. Sanderink, and J. M. Scherrmann. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br. J. Pharmacol. 138:1367-1375 (2003).
7. M. F. Fromm, R. B. Kim, C. M. Stein, G. R. Wilkinson, and D. M. Roden. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557 (1999).
8. D. K. Yu. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 39:1203-1211 (1999).
9. Q. R. Smith. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. In R. T. Borchardt, P. L. Smith, G. Wilson, (eds). Models for assessing drug absorption and metabolism, Vol. 8. New York, Plenum Press, pp. 285-307 (1996).
10. S. Cisternino, C. Rousselle, C. Dagenais, and J. M. Scherrmann. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm. Res. 18:183-190 (2001).
11. M. Garrigos. L. M. Mir, and S. Orlowski. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase -further experimental evidence for a multisite model. Eur. J. Biochem. 244:664-673 (1997).
12. C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton, and R. Callaghan. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:624-632 (2000).
13. A. B. Shapiro. K. Fox, P. Lam, and V. Ling. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 259:841-850 (1999).
14. C. Dagenais. C. Rousselle, G. M. Pollack, and J. M. Scherrmann. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein deficient mice. J. Cereb. Blood Flow Metab. 20:381-386 (2000).
15. W. D. Stein. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev. 77:545-590 (1997).
16. Y. Takasato, S. I. Rapoport, and Q. R. Smith. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247:H484-H493 (1984).
17. S. Cisternino, C. Rousselle, M. Debray, and J. M. Scherrmann. In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier. Pharm. Res. 20:1607-1611 (2003).
18. M. Ponec. J. Kempenaar, B. Shroot, and J. C. Caron. Glucocorticoids: binding affinity and lipophilicity. J. Pharm. Sci. 75:973-975 (1986).
19. G. Klopman, L. M. Shi, and A. Ramu. Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol. Pharmacol. 52:323-334 (1997).
20. T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D. D. Ross, K. Miyake, J. H. Resau, and S. E. Bates. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113:2011-2021 (2000).
21. K. Tunblad, E. N. Jonsson, and M. Hammarlund-Udenaes. Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm. Res. 20:618-623 (2003).
22. J. Van Asperen, O. Van Tellingen, A. H. Schinkel, and J. H. Beijnen. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. J. Pharmacol. Exp. Ther. 289:329-333 (1999).
23. S. Scala and N. Akhmed. U. S. Rao, K. Paull, L. B. Lan, B. Dickstein, J. S. Lee, G. H. Elgemeie, W. D. Stein, and S. E. Bates. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 51:1024-1033 (1997).
24. A. Garrigues, N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, and S. Orlowski. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol. Pharmacol. 62:1288-1298 (2002).
25. P. Gros, R. Dhir, J. Croop, and F. A. Talbot. Single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc. Natl. Acad. Sci. USA 88:7289-7293 (1991).
26. F. J. Sharom, P. Lu, R. Liu, and X. Yu. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochem. J. 333:621-630 (1998).
27. R. Callaghan and J. R. Riordan. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268:16059-16064 (1993).
28. S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L. B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. 61:964-973 (2002).
29. S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L. B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61:974-981 (2002).
30. R. H. Stephens, C. A. O'Neill, A. Warhurst, G. L. Carlson, M. Rowland, and G. Warhurst. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296:584-591 (2001).
31. S. V. Ambudkar, C. O. Cardarelli, I. Pashinsky, and W. D. Stein. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J. Biol. Chem. 272:21160-21166 (1997).
32. S. Orlowski, L. M. Mir, J. JR Belehradek, and M. Garrigos. Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem. J. 317:515-522 (1996).
33. E. J. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity. Arch. Biochem. Biophys. 383:91-98 (2000).
34. L. B. Lan, S. Ayesh, E. Lyubimov, I. Pashinsky, and W. D. Stein. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother. Pharmacol. 38:181-190 (1996).
35. M. Arboix, O. G. Paz, T. Colombo, and M. D'Incalci. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther. 281:1226-1230 (1997).
36. E. Lyubimov, L. B. Lan, I. Pashinsky, and W. D. Stein. Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anticancer Drugs 7:60-69 (1996).
37. M. Lemaire, A. Bruelisauer, P. Guntz, and H. Sato. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother. Pharmacol. 38:481-486 (1996).
38. N. Simon, E. Dailly, O. Combes, E. Malaurie, M. Lemaire, J. P. Tillement, and S. Urien. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br. J. Clin. Pharmacol. 45:173-175 (1998).
39. W. M. Pardridge and E. M. Landaw. Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesis. J. Clin. Invest. 74:745-752 (1984).
40. H. Tanaka and K. Mizojiri. Drug-protein binding and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. 288:912-918 (1999).
41. Y. Adachi, H. Suzuki, and Y. Sugiyama. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18:1660-1668 (2001).